Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,617
Employees2,617
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,617
Employees2,617

INCY Key Statistics

Market cap
20.55B
Market cap20.55B
Price-Earnings ratio
17.22
Price-Earnings ratio17.22
Dividend yield
Dividend yield
Average volume
2.05M
Average volume2.05M
High today
$105.53
High today$105.53
Low today
$101.00
Low today$101.00
Open price
$102.46
Open price$102.46
Volume
1.57M
Volume1.57M
52 Week high
$112.29
52 Week high$112.29
52 Week low
$53.56
52 Week low$53.56

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $105.53. The company's market cap stands at 20.55B, with a P/E ratio of 17.22.

On 2026-01-22, Incyte(INCY) stock moved within a range of $101.00 to $105.53. With shares now at $105.53, the stock is trading +4.5% above its intraday low and 0.0% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 1.57M, versus its average volume of 2.05M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.

INCY News

Simply Wall St 1d
Is Incyte Pricing Reflect Its Strong 1-Year Rally And DCF Upside Potential

If you are wondering whether Incyte's recent share price puts it at a bargain or a stretch, this article walks through what the numbers are currently saying abo...

Is Incyte Pricing Reflect Its Strong 1-Year Rally And DCF Upside Potential
TipRanks 2d
Wells downgrades Incyte to Equal Weight on lack of catalysts

Wells Fargo downgraded Incyte (INCY) to Equal Weight from Overweight with a price target of $107, down from $116. The firm says its upgrade thesis has largely p...

TipRanks 2d
Incyte downgraded to Equal Weight from Overweight at Wells Fargo

Wells Fargo downgraded Incyte (INCY) to Equal Weight from Overweight with a $107 price target Published first on TheFly – the ultimate source for real-time, ma...

Analyst ratings

50%

of 28 ratings
Buy
39.3%
Hold
50%
Sell
10.7%

More INCY News

Simply Wall St 5d
Assessing Incyte Valuation After Strong 1 Year Returns And Recent Share Price Momentum

Advertisement Why Incyte (INCY) Is On Investors' Radar Today Incyte (INCY) is back in focus after recent share price moves and fresh attention on its pipeline...

Assessing Incyte Valuation After Strong 1 Year Returns And Recent Share Price Momentum
TipRanks 6d
Incyte Advances Microneedle Skin Sampling Platform With Completion of Observational Study in Atopic Dermatitis

Incyte (INCY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Incyte’s latest clinical update centers on a Phase 0 observa...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.